By continuing to use this site you consent to the use of cookies on your device. Find out more about our cookie policy and the types of cookies we use by clicking here

AXA Framlington Biotech R Class Acc

Performance History28/02/2017
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech R Class Acc
Fund63.745.311.2-5.98.7
+/-Cat8.66.7-2.3-1.9-2.8
+/-B’mrk-1.06.3-2.7-10.7-0.1
 
Key Stats
NAV
24/03/2017
 GBX 163.40
Day Change -0.55%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
28/02/2017
 GBP 530.05
Share Class Size (Mil)
24/03/2017
 GBP 146.08
Max Initial Charge 5.50%
Ongoing Charge
17/02/2017
  1.82%
Investment Objective: AXA Framlington Biotech R Class Acc
The objective is to provide long-term capital appreciation by investing principally in equity securities of companies in biotechnology, genomic and medical research industries worldwide.
Returns
Trailing Returns24/03/2017
YTD5.01
3 Years Annualised13.53
5 Years Annualised23.00
10 Years Annualised16.17
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Dani Saurymper
01/04/2015
Inception Date
26/11/2001
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMSCI World/Biotechnology NR USD
Portfolio Profile for  AXA Framlington Biotech R Class Acc28/02/2017
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock98.200.0098.20
Bond0.000.000.00
Property0.000.000.00
Cash2.240.831.41
Other0.390.000.39
Top 5 Regions%
United States89.99
Eurozone4.60
Europe - ex Euro3.39
United Kingdom1.70
Canada0.32
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Celgene CorpHealthcareHealthcare8.96
Biogen IncHealthcareHealthcare8.45
Gilead Sciences IncHealthcareHealthcare8.33
Alexion Pharmaceuticals IncHealthcareHealthcare6.88
Amgen IncHealthcareHealthcare6.10
AXA Framlington Biotech R Class Acc